Eli Lilly Sues Actavis To Block Generic ADHD Drug
Eli Lilly & Co. has filed a lawsuit against a U.S. subsidiary of Iceland-based Actavis, looking to stave off generic competition in the $509 million annual U.S. market for the attention-deficit...To view the full article, register now.
Already a subscriber? Click here to view full article